|
Avaliação DCF Surmodics, Inc. (SRDX)
US | Healthcare | Medical - Devices | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Surmodics, Inc. (SRDX) Bundle
Aprimore suas estratégias de investimento com a calculadora DCF Surmodics, Inc. (SRDX)! Explore os dados financeiros mais recentes de Surmodics, ajuste as projeções e despesas de crescimento e observe instantaneamente como essas modificações afetam o valor intrínseco da Surmodics, Inc. (SRDX).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 94.9 | 105.1 | 100.0 | 132.6 | 126.1 | 136.7 | 148.2 | 160.6 | 174.1 | 188.8 |
| Revenue Growth, % | 0 | 10.83 | -4.93 | 32.65 | -4.91 | 8.41 | 8.41 | 8.41 | 8.41 | 8.41 |
| EBITDA | 5.9 | 12.2 | -12.2 | 15.2 | 1.2 | 4.9 | 5.3 | 5.8 | 6.3 | 6.8 |
| EBITDA, % | 6.26 | 11.58 | -12.23 | 11.43 | 0.94227 | 3.6 | 3.6 | 3.6 | 3.6 | 3.6 |
| Depreciation | 7.5 | 8.3 | 9.7 | 9.2 | 8.7 | 10.7 | 11.7 | 12.6 | 13.7 | 14.8 |
| Depreciation, % | 7.92 | 7.92 | 9.68 | 6.92 | 6.9 | 7.86 | 7.86 | 7.86 | 7.86 | 7.86 |
| EBIT | -1.6 | 3.8 | -21.9 | 6.0 | -7.5 | -5.8 | -6.3 | -6.9 | -7.4 | -8.1 |
| EBIT, % | -1.65 | 3.66 | -21.91 | 4.51 | -5.95 | -4.27 | -4.27 | -4.27 | -4.27 | -4.27 |
| Total Cash | 61.1 | 38.9 | 19.0 | 45.4 | 40.1 | 51.0 | 55.2 | 59.9 | 64.9 | 70.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 16.2 | 22.9 | 24.2 | 23.9 | 23.2 | 27.2 | 29.5 | 32.0 | 34.6 | 37.6 |
| Account Receivables, % | 17.05 | 21.79 | 24.21 | 18.03 | 18.37 | 19.89 | 19.89 | 19.89 | 19.89 | 19.89 |
| Inventories | 6.0 | 6.8 | 11.8 | 14.8 | 15.2 | 13.1 | 14.2 | 15.3 | 16.6 | 18.0 |
| Inventories, % | 6.29 | 6.43 | 11.82 | 11.19 | 12.03 | 9.55 | 9.55 | 9.55 | 9.55 | 9.55 |
| Accounts Payable | 1.5 | 1.8 | 3.1 | 3.0 | .0 | 2.4 | 2.6 | 2.8 | 3.0 | 3.3 |
| Accounts Payable, % | 1.6 | 1.7 | 3.14 | 2.26 | 0 | 1.74 | 1.74 | 1.74 | 1.74 | 1.74 |
| Capital Expenditure | -3.7 | -6.3 | -3.4 | -2.9 | -3.5 | -5.0 | -5.4 | -5.8 | -6.3 | -6.9 |
| Capital Expenditure, % | -3.87 | -5.97 | -3.37 | -2.2 | -2.77 | -3.64 | -3.64 | -3.64 | -3.64 | -3.64 |
| Tax Rate, % | -53.77 | -53.77 | -53.77 | -53.77 | -53.77 | -53.77 | -53.77 | -53.77 | -53.77 | -53.77 |
| EBITAT | 1.2 | 2.6 | -26.5 | -3.7 | -11.5 | -3.1 | -3.4 | -3.7 | -4.0 | -4.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -15.6 | -2.7 | -25.2 | -.3 | -8.9 | 3.1 | -.3 | -.3 | -.3 | -.4 |
| WACC, % | 9.03 | 9.5 | 9.74 | 9.03 | 9.74 | 9.4 | 9.4 | 9.4 | 9.4 | 9.4 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | -5 | |||||||||
| Present Terminal Value | -3 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | -3 | |||||||||
| Equity Value | 1 | |||||||||
| Diluted Shares Outstanding, MM | 14 | |||||||||
| Equity Value Per Share | 0.10 |
What You Will Get
- Real SRDX Financial Data: Pre-filled with Surmodics, Inc.’s historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Surmodics, Inc.’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Surmodics, Inc. (SRDX).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable inputs specific to Surmodics, Inc. (SRDX).
- Customizable Forecast Assumptions: Easily modify growth rates, capital expenditures, and discount rates for accurate projections.
- Integrated Financial Ratios: Assess profitability, leverage, and efficiency ratios relevant to Surmodics, Inc. (SRDX).
- Interactive Dashboard and Charts: Visual representations highlight key valuation metrics for straightforward analysis.
How It Works
- Download: Get the pre-prepared Excel file containing Surmodics, Inc.'s (SRDX) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various forecasts and compare results immediately.
- Make Decisions: Utilize the valuation outcomes to inform your investment strategy.
Why Choose This Calculator for Surmodics, Inc. (SRDX)?
- Accurate Data: Utilize real Surmodics financials for trustworthy valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants focused on Surmodics.
- User-Friendly: Easy-to-navigate design and clear instructions cater to users of all experience levels.
Who Should Use Surmodics, Inc. (SRDX)?
- Healthcare Professionals: Understand the latest advancements in medical device technologies and their applications.
- Researchers: Utilize data from Surmodics, Inc. (SRDX) to enhance studies in drug delivery systems.
- Investors: Analyze market trends and evaluate investment opportunities related to Surmodics, Inc. (SRDX).
- Business Analysts: Leverage customizable financial models to assess Surmodics, Inc. (SRDX) performance.
- Medical Device Entrepreneurs: Gain insights into the strategies used by established companies like Surmodics, Inc. (SRDX).
What the Template Contains
- Pre-Filled Data: Includes Surmodics, Inc.'s (SRDX) historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Surmodics, Inc.'s (SRDX) profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.